Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 2
2004 1
2005 1
2006 2
2007 4
2008 3
2009 3
2010 5
2011 2
2012 1
2013 2
2014 1
2015 2
2016 2
2017 9
2018 2
2019 6
2020 3
2021 9
2022 7
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance.
Chu Y, Dai E, Li Y, Han G, Pei G, Ingram DR, Thakkar K, Qin JJ, Dang M, Le X, Hu C, Deng Q, Sinjab A, Gupta P, Wang R, Hao D, Peng F, Yan X, Liu Y, Song S, Zhang S, Heymach JV, Reuben A, Elamin YY, Pizzi MP, Lu Y, Lazcano R, Hu J, Li M, Curran M, Futreal A, Maitra A, Jazaeri AA, Ajani JA, Swanton C, Cheng XD, Abbas HA, Gillison M, Bhat K, Lazar AJ, Green M, Litchfield K, Kadara H, Yee C, Wang L. Chu Y, et al. Among authors: jazaeri aa. Nat Med. 2023 Jun;29(6):1550-1562. doi: 10.1038/s41591-023-02371-y. Epub 2023 May 29. Nat Med. 2023. PMID: 37248301
Immuno-Oncology for Gynecologic Malignancies.
How JA, Patel A, Jazaeri AA. How JA, et al. Among authors: jazaeri aa. Adv Exp Med Biol. 2021;1342:193-232. doi: 10.1007/978-3-030-79308-1_6. Adv Exp Med Biol. 2021. PMID: 34972966 Review.
Immunotherapy in Gynecologic Cancers: Are We There Yet?
Pakish JB, Jazaeri AA. Pakish JB, et al. Among authors: jazaeri aa. Curr Treat Options Oncol. 2017 Aug 24;18(10):59. doi: 10.1007/s11864-017-0504-y. Curr Treat Options Oncol. 2017. PMID: 28840453 Free PMC article. Review.
Transforming ovarian cancer care by targeting minimal residual disease.
Jazaeri AA, Grisham R, Knisely A, Spranger S, Zamarin D, Hillman RT, Lawson BC, Burns KH, Lee S, Westin SN, Moiso E, Williams MJ, Bardhan NM, Pisanic T, Matulonis U, Weigelt B, Shih I, Konstantinopoulos PA, Gaillard S, Wang L, Aghajanian C, D'Andrea AD, Hammond P, Shah S, Wucherpfennig KW, Lu KH. Jazaeri AA, et al. Med. 2023 Nov 10;4(11):755-760. doi: 10.1016/j.medj.2023.08.004. Med. 2023. PMID: 37951209
CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling.
Fix SM, Forget MA, Sakellariou-Thompson D, Wang Y, Griffiths TM, Lee M, Haymaker CL, Dominguez AL, Basar R, Reyes C, Kumar S, Meyer LA, Hwu P, Bernatchez C, Jazaeri AA. Fix SM, et al. Among authors: jazaeri aa. J Immunother Cancer. 2022 Jul;10(7):e003750. doi: 10.1136/jitc-2021-003750. J Immunother Cancer. 2022. PMID: 35882447 Free PMC article.
79 results